Treatment Details – 10.0 months
|Patients: This Phase I/II study involved 28 patients with malignant pleural mesothelioma.|
Treatment: The treatment consisted of surgery (pleuropneumonectomy) with intraoperative photodynamic therapy (the drug mTHPC). (Photodynamic therapy is a technique that uses non-thermal lasers to activate light-sensitive drugs.)
Toxicity: Three patients died in the perioperative period (the period immediately preceding, during and after a surgical procedure.) One of the three deaths was directly related to photodynamic therapy.
Results: The overall median survival time was 10 months.
Support: The study was supported in part by Scotia Pharmaceuticals, Ltd. Scotia manufactures the drug, mTHPC.
Correspondence: Paul Bass, MD, PhD